Johnson & Johnson’s hematology portfolio: breakthroughs to watch
Description
Welcome to our final episode for 2025. We’re taking a little break for the holidays but we’ll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA’s M Ventures, Hakan Goker.
Today, though, I’m joined by Ester in t’Groen of Johnson & Johnson.
Fresh off the American Society of Hematology (ASH) Annual Meeting in Orlando, where J&J presented over 60 abstracts, Ester shares insights into the company's portfolio and the advances that the company has made over recent years in the hematology space.
She walks us through the real-world evidence for some pretty significant results from the thousands of patients in their clinical trials, and explain what's next for J&J in hematology in 2026—including some exciting readouts.
01:14 - Meet Ester in t'Groen
02:37 - Winning the Kilmer Medal
06:32 - J&J's key focus areas
07:32 - The hematology portfolio
19:07 - All about ASH 2025
23:49 - The MajesTEC-3 data
27:43 - The value of real-world datasets
32:06 - Looking forward into 2026
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
United States
